title: Combined treatment using peripheral nerve graft and FGF-1: changes to the glial environment and differential macrophage reaction in a complete transected spinal cord.
abstract: We used a complete spinal cord transection model in which the T8 spinal segment was removed to study the effect of combined treatment of peripheral nerve graft and application of FGF-1 on the glial environment. The combined treatment resulted in reduced astrocytic glial scarring, reactive macrophage gliosis, and inhibitory proteoglycan in the back-degenerated white matter tract. While the macrophage activities in the back-degenerative tract were down-regulated, those in the grafted peripheral nerves and in the distal Wallerian degenerative tracts were not. We concluded that the combined treatment changed the glial environment in the back-degenerative tract, and differentially regulated the macrophage activities in the system, in favor of CNS regeneration.
authors.affiliation: Graduate Institute of Biotechnology, Chaoyang University of Technology, Taichung, Taiwan.
authors.forename: Meng-Jen
authors.initials: MJ
authors.lastname: Lee
authors.forename: Ching Jung
authors.initials: CJ
authors.lastname: Chen
authors.forename: Chu-Hsun
authors.initials: CH
authors.lastname: Cheng
authors.forename: Wen-Cheng
authors.initials: WC
authors.lastname: Huang
authors.forename: Huai-Sheng
authors.initials: HS
authors.lastname: Kuo
authors.forename: Jau-Ching
authors.initials: JC
authors.lastname: Wu
authors.forename: May J
authors.initials: MJ
authors.lastname: Tsai
authors.forename: Ming-Chao
authors.initials: MC
authors.lastname: Huang
authors.forename: Wen-Chi
authors.initials: WC
authors.lastname: Chang
authors.forename: Henrich
authors.initials: H
authors.lastname: Cheng
mesh_terms: D000818:Animals; D001253:Astrocytes / Q000187:drug effects / Q000502:physiology; D015415:Biomarkers / Q000032:analysis / Q000378:metabolism; D004195:Disease Models, Animal; D015536:Down-Regulation / Q000187:drug effects / Q000502:physiology; D005260:Female; D016220:Fibroblast Growth Factor 1 / Q000494:pharmacology* / Q000627:therapeutic use; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D005911:Gliosis / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D006085:Graft Survival / Q000187:drug effects / Q000502:physiology; D008264:Macrophages / Q000187:drug effects / Q000502:physiology; D009416:Nerve Regeneration / Q000187:drug effects / Q000502:physiology; D009434:Neural Pathways / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D009457:Neuroglia / Q000187:drug effects / Q000502:physiology; D010525:Peripheral Nerves / Q000166:cytology / Q000502:physiology / Q000637:transplantation*; D011509:Proteoglycans / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D013119:Spinal Cord Injuries / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery*; D016378:Tissue Transplantation / Q000379:methods*; D016896:Treatment Outcome; D014855:Wallerian Degeneration / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control
chemical_list: D015415:Biomarkers; D005904:Glial Fibrillary Acidic Protein; D011509:Proteoglycans; D016220:Fibroblast Growth Factor 1